BriaCell Therapeutics Corp.
BCTXDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How BCTX's past catalysts played out
SV-BR-1-GM
Breastcancer
Interferon infiltration of the inoculation site
Breast Cancer
BC1 cell line
Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SV-BR-1-GM | Phase 3 | Breastcancer | - | - |
Interferon infiltration of the inoculation site | Phase 3 | Breast Cancer | - | - |
BC1 cell line | Phase 2 | Breast Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BriaCell Therapeutics Corp.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in BriaCell Therapeutics Corp.'s (BCTX) pipeline across Phase 3, Phase 2. Its lead program is SV-BR-1-GM (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BriaCell Therapeutics Corp.'s next FDA catalyst?→
BriaCell Therapeutics Corp.'s (BCTX) next tracked catalyst is a Earnings expected October 21, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BCTX biotech catalysts?→
Add BCTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BriaCell Therapeutics Corp.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.